Patent focus: inhibitors of tumour cell growth

Bibliography

• BUOLAMWINI JK: Novel anticancer drug discovery. Curr. Opin. Chem. Biol. (1999) 3(4):500–509.
   PubMed Web of Science ®Google Scholar
• ULLRICH A, SCHLESSINGER J: Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 61:202–212.
   Web of Science ®Google Scholar
• FANTL WJ, JOHNSON DE, WILLIAMS LT: Signalling byreceptor tyrosine kinases. Ann. Rev. Biochem. (1993) 62:453–481.
   PubMed Web of Science ®Google Scholar
• PELES E, YARDEN Y: Neu and its ligands: from anoncogene to neural factors. Bioessays (1993) 15:815–824.
   PubMed Web of Science ®Google Scholar
• ALROY I, YARDEN Y: The ErbB signaling network in and oncogenesis: signal diversifica-tion through combinatorial ligand-receptor interac-tions. FEBS Lett. (1997) 410:83–86.
   PubMed Web of Science ®Google Scholar
• •Article outlining signaling pathways of members of the Type receptor tyrosine kinase family.
   Google Scholar
• HELDIN C: Dimerization of cell surface receptors in signal transduction. Cell (1995) 80:213–223.
   PubMed Web of Science ®Google Scholar
• FRY DW, KRAKER AJ, MCMICHAEL A et al.: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (1994) 265:1093–1095.
   PubMed Web of Science ®Google Scholar
• BRIDGES AJ: The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor family of tyrosine kinases. Curr. Med. Chem. (1999) 6:825–843.
   PubMed Web of Science ®Google Scholar
• FRY DW: Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol. Ther. (1999) 82 (2-3) :207–218.
   PubMed Web of Science ®Google Scholar
• •Recent review covering the development of irreversible inhibitors of EGFR.
   Google Scholar
• KLOHS WD, FRY DW, KRAKER AJ: Inhibitors of tyrosine kinase. Curr. Opin. Oncol. (1997) 9:562–568.
   PubMedGoogle Scholar
• BOSCHELLI DH: Small molecule inhibitors of receptor tyrosine kinases. Drugs of the Future (1999) 24 (5):515–537.
   Google Scholar
• TRAXLER P, FURET P: Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. (1999) 82(2-3):195–206.
   PubMed Web of Science ®Google Scholar
• STRAWN LM, SHAWVER LK: Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp. Opin. Invest. Drugs (1998) 7(4):553–573.
   PubMedGoogle Scholar
• MENDELSOHN J, FAN Z: Epidermal growth factor family and chemosensitization. J. Nati Cancer Inst. (1997) 89 (5) 341–343.
   PubMed Web of Science ®Google Scholar
• ALBANELL J, BASELGA J: Trastuzumab, a humanized anti-HER2 monoclonal antibody for the treatment of breast cancer. Drugs Today (1999) 35(12):931–946.
   PubMed Web of Science ®Google Scholar
• HAMBY JM, SHOWALTER HDH: Small molecule inhibi-tors of tumor promoted angiogenesis, including protein tyrosine kinase inhibitors. Pharmacol. Ther. (1999) 82 (2-3) :169–193.
   PubMed Web of Science ®Google Scholar
• CONNELL RD: Patent focus on cancer chemotherapeu-tics - angiogenesis agents: October 1999 - March 2000. Exp. Opin. Ther. Patents (2000) 10(6):767–786.
   Web of Science ®Google Scholar
• FRY DW, BRIDGES AJ, DENNY WA: Specific irreversible inactivation of the epidermal growth factor receptor and erbB2: by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA (1998) 95:12022–12027.
   PubMed Web of Science ®Google Scholar
• SUN L, TRAN N, HANG C et al.: Design, synthesis and evaluations of substituted 34(3- or 4 - carboxyethylpyrrol-2-y0 methylidenyl]. indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. j Med. Chem. (1999) :42 (25):5120–5130.
   Google Scholar
• WALCH TE, MARCHETTI D: Role of neurotrophins and neurotrophin receptors in the in vitro invasion and heparanase production of human prostate cancer cells. Clin. Exp. Metastasis (1999):17(4):307–314.
   PubMed Web of Science ®Google Scholar
• DIONNE CA, CAMORATTO AM, JANI JP et. al: Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin. Cancer Res. (1998) 4(8):1887–1898.
   Google Scholar
• UCKUN, FM: Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem. Pharmacol. (1998) 56(6):683–691.
   PubMed Web of Science ®Google Scholar
• Leflunomide. Drugs of the Future (1998) 23(8):827–837.
   Google Scholar
• LIPSON KE, WANG X, CHEN H et al.: SU101 and not its major metabolite, inhibits PDGF-dependent receptor tyrosine phosphorylation, cell cycle progression and human tumor growth. Proc. Am. Assoc. Cancer Res. (1998) 39:Abstract 3797.
   Google Scholar
• SICHERI F, MOAREFI I, KURIYAN J: Crystal structure of family kinase Hck. Nature (1 9 9 7)385(6617)602–609.
   Google Scholar
• MOHAMMADI M, MCMAHON, G et al: Structures of thetyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science (1997) 276:955–960.
   PubMed Web of Science ®Google Scholar
• HUBBARD SR: Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. (1 9 9 7) 16(18):5572–5581.
   Google Scholar
• KARLSSON R, ZHENG J, XUONG NH, TAYLOR SS, SOWADSKI JM: Structure of the mammalian catalytic subunit of cAMP-dependent protein kinase and an inhibitor peptide displays an open conformation. Acta Crystallogr., Sect. D: Biol. Crystallogr. (1993) D49 (4):381–8.
   Google Scholar
• SHERR CJ: Cancer cell cycles. Science (1996) 274:1672–1677.
   PubMed Web of Science ®Google Scholar
• DELSAL G, LODA M, PAGANO M: Cell cycle and cancer: critical events at the G1 restriction point. Crit. Rev. Oncog. (1996) 7(1-2):127–142.
   PubMed Web of Science ®Google Scholar
• WEBSTER KR: The therapeutic potential of targeting the cell cycle. Exp. Opin. Invest. Drugs (1998) 7:865–887.
   PubMedGoogle Scholar
• SHAPIRO GI, HARPER JW: Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest. (1999) 104 (12): 1645–1653.
   PubMed Web of Science ®Google Scholar
• GARRETT MD, FATTAEY A: Cdk inhibition and cancer therapy. Curr. Opin. Genet. Dev. (1999) 9:104–111.
   PubMed Web of Science ®Google Scholar
• ROSANIA GR, CHANG Y: Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors. Exp. Opin. Ther. Patents (2000) 10(2):215–230.
   Web of Science ®Google Scholar
• SIELECKI TM, BOYLAN JF, BENFIELD PA, TRAINOR GL: Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. (2000) 43(1):1–18.
   PubMed Web of Science ®Google Scholar
• •Very thorough recent review on cdk inhibitors.
   Google Scholar
• GRAY N, DETIVAUD L, DOERIG C, LAURENT M: ATP-site inhibitors of cyclin-dependent kinases. Curr. Merl. Chem. (1999) 6(9):859–875.
   PubMed Web of Science ®Google Scholar
• MEIJER L, LECLERC S, LEOST M: Properties and potential applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther. (1 9 9 9) 82 (2–3):279–284.
   Google Scholar
• SENDEROWICZ AM, SAUSVILLE EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (2000) 92 (5):376–387.
   PubMed Web of Science ®Google Scholar
• •Report detailing the background of the cdk inhibitors flavopiridol and UCN-01 and their progress in clinical trials.
   Google Scholar
• ECKER G: Patent focus on agents for tumour therapy: May - October 1999. Exp. Opin. Ther. Patents (1999) 9(12):1627–1639.
   Web of Science ®Google Scholar
• SCHULTZ C, LINK A, LEOST M et al.: Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evalua-tion of CDK1/cyclin B inhibition and in vitro antitumor activity. J. Med. Chem. (1 9 9 9) 42 (15):2909–2919.
   Google Scholar
• KUNICK C, SCHULTZ C, LEMCKE T et al: 2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity. Bioorg. Merl. Chem. Lett. (2000) 10(6) :567–569.
   PubMed Web of Science ®Google Scholar
• DE AZEVEDO WF, MUELLER-DIECKMANN HJ et al: Structural basis for specificity and potency of a flavonoid inhibitor of human cdk2: a cell cycle kinase. Proc. Natl. Acad. ScL USA (1996) 93(7):2735–2740.
   PubMed Web of Science ®Google Scholar
• RUOSLAHTI E: Fibronectin and its integrin receptors in cancer. Adv. Cancer Res. (1999) 76:1–20.
   PubMed Web of Science ®Google Scholar
• WEYANT MJ, CAROTHERS AM, BERTAGNOLLI ME, BERTAGNOLLI MM: Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways. Clin. Cancer Res. (2000) 6(3):949–956.
   PubMed Web of Science ®Google Scholar
• LEONARD DM: Ras farnesyltransferase a new therapeutic target. J. Med. Chem. (1997) 40(19)2971–2990.
   Google Scholar
• OLIFF A: Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim. Biophys. Acta (1999) 1423(3) :C19–30.
   Web of Science ®Google Scholar
• KOHL NE: Farnesyltransferase inhibitors in preclinical development. Ann. NY Acad. Sci. (1999) 886(Anticancer Molecules):91–102.
   Google Scholar
• NEVILLE J, GOMEZ RP, SCHABER MD et al: Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase. J. Merl. Chem. (1 9 9 9) 42(17)3356–3368.
   Google Scholar
• TAVERAS AG, DESKUS J, CHAO J et al.: Identification of pharmacokinetically stable 3,10-dibromo-8-chlorobenzocyclohetapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities. J. Merl. Chem. (1999) 42(14)2651–2661.
   Google Scholar
• WILLIAMS TM, DINSMORE CJ: Farnesyl transferase inhibitors: design of a new class of cancer therapeutic agents. Adv. Med. Chem. (1999) 4:273–314.
   Google Scholar
• WILLIAMS TM: Inhibitors of protein farnesylation 1998. Exp. Opin. Ther. Patents (1998) 8(5):553–569.
   Web of Science ®Google Scholar
• ADJEI AA, ERLICHMAN C, DAVIS JN et al.: A Phase I trial of the farnesyl transferase inhibitor SCH: evidence for biological and clinical activity. Cancer Res. (2000) 60(7) :1871–1877.
   PubMed Web of Science ®Google Scholar
• ZUJEWSKI J, HORAK ID, BOL CJ et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. (2000) 18 (4) :927–941.
   PubMed Web of Science ®Google Scholar
• END DW: Farnesyl transferase inhibitors and other therapies targeting the ras signal transduction pathway. Invest. New Drugs (1999) 17(3):241–258.
   PubMed Web of Science ®Google Scholar
• STRICKLAND CL, WINDSOR WT, SYTO R et al: Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogs. Biochemistry (1998) 37 (47) :16601–16611.
   PubMed Web of Science ®Google Scholar
• STRICKLAND CL, WEBER PC, WINDSOR WT et al.: Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity-relationships. J. Med. Chem. (1999) 42 (12):2125–2135.
   PubMed Web of Science ®Google Scholar
• STRICKLAND CL, WEBER PC: Farnesyl protein transfe-rase: a review of structural studies. Curr. Opin. Drug Disc. Dev. (1999) 2(5):475–483.
   PubMedGoogle Scholar
• •Recent review on efforts involving crystallisation of FPT/FPP/inhibitor complexes.
   Google Scholar
• CAMPBELL MJ, KOEFFLER PH: Toward therapeutic intervention of cancer by vitamin D compounds. J. Natl. Cancer Inst. (1997) 89 (3) :182–185.
   PubMedGoogle Scholar
• BOUILLON R, VERSTUYF A, VERLINDER L et al.:Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochem. Pharmacol.
   Google Scholar